Pharmaceutical

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).

Jan 13, 2024 - 18:00
Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke
Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).
Read the original article

Tags:

Previous Article

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Next Article

ClinChoice enhances global reach with CSI Medical acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Antengene’s multiple myeloma therapy receives approval in Hong Kong

Antengene’s multiple myeloma therapy receives approval ...

Jul 17, 2023

BioAtla receives FDA fast track designation for ozuriftamab vedotin

BioAtla receives FDA fast track designation for ozurift...

Jul 26, 2024

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

Lykos cuts team by 75%, vows to keep MDMA program despi...

Aug 17, 2024